Saxenda is a medicine used along with diet and increased physical activity to help manage weight in: - adults with obesity (BMI of 30 or more); - adults with overweight (BMI between 27 and 30) and weight-related complications such as diabetes, abnormally high levels of fat in the blood, high blood pressure or obstructive sleep apnoea (frequent interruption of breathing during sleep); - adolescents from 12 years of age with obesity (BMI of 30 or more for adults by international age and gender related cut-off points) who weigh more than 60 kg; - children from 6 to less than 12 years of age with obesity (BMI at or above the 95th percentile) who weigh at least 45 kg. BMI (body mass index) is a measure of your weight in relation to your height. A BMI at the 95th percentile means that it is greater than that of 95% of people of the same age and gender. Saxenda contains the active substance liraglutide.
Therapeutic Indication
### Therapeutic indication Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of • ≥ 30 kg/m² (obese), or • ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. Treatment with Saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight. Adolescents (≥12 years) Saxenda can be used as an adjunct to a healthy nutrition and increased physical activity for weight management in adolescent patients from the age of 12 years and above with: - obesity (BMI corresponding to ≥30 kg/m2 for adults by international cut-off points)\* and - body weight above 60 kg. Treatment with Saxenda should be discontinued and re-evaluated if patients have not lost at least 4% of their BMI or BMI z score after 12 weeks on the 3.0 mg/day or maximum tolerated dose. \*IOTF BMI cut-off points for obesity by sex between 12-18 years, in accordance with study design of the Trial 4180, see section 5.1. Children (6 to <12 years) Saxenda is indicated as an adjunct to healthy nutrition and increased physical activity for weight management in children from the age of 6 to <12 years with \- obesity (BMI ≥95th percentile)\* and \- body weight ≥45 kg Treatment with Saxenda should be discontinued and re-evaluated if patients have not lost at least 4% of their BMI or BMI z score after 12 weeks on the 3.0 mg/day or maximum tolerated dose. \*CDC BMI cut-off points for obesity (≥95th percentile) by sex between 6 to <12 years, in accordance with study design of the Trial 4392, see section 5.1.
Therapeutic Area (MeSH)
ATC Code
A10BJ02
ATC Item
liraglutide
Pharmacotherapeutic Group
Drugs used in diabetes
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| liraglutide | N/A | 利拉鲁肽 |
EMA Name
Saxenda
Medicine Name
Saxenda
Aliases
N/A
